Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 3/20 | 0.44 |
| ▸ | HINT1 | P49773 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL930787 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL930789 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL6365090 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL30378647 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL19777955 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL24829628 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL14652919 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL17453217 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL2484115 | 0.94 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL2484116 | 0.94 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667053-A2 | BETA-D-2'-DEOXY-2'ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | ATEA Pharmaceuticals, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-3265102-B1 | BETA-D-2'-DEOXY-2'ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | ATEA PHARMACEUTICALS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250243235-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12084473-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2024-09-10 | — | — | US | disclosed |
| US-11975016-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | Atea Pharmaceuticals, Inc. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240002426-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230310481-A1 | BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. | 2023-10-05 | — | — | US | disclosed |
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3013340-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20100286083-A1 | NUCLEOSIDE ANALOGS | PHARMASSET, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100279973-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PHARMASSET, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2010075554-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PHARMASSET, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010075549-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010075517-A2 | NUCLEOSIDE ANALOGS | PHARMASSET, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010075549-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2009152095-A2 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152095-A2 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279973-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PNP, NUDT1, TYMP | NT5E 64/4885HINT1 75/4885LMNA 1983/4885 |
| US-20230310481-A1 | BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | NME2, HAVCR2, NME1 | NT5E 88/4885HINT1 391/4885LMNA 1088/4885 |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | NT5E 15/4885HINT1 83/4885LMNA 2079/4885 |
| US-12084473-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | NT5E 49/4885HINT1 497/4885LMNA 1327/4885 |
| US-11975016-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | NSUN2, ADAR, NSUN3 | NT5E 90/4885HINT1 296/4885LMNA 2347/4885 |
| US-20250243235-A1 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | NT5E 62/4885HINT1 572/4885LMNA 1290/4885 |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | NT5E 51/4885HINT1 111/4885LMNA 1306/4885 |
| US-20240002426-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | NT5E 62/4885HINT1 572/4885LMNA 1290/4885 |
| US-20100286083-A1 | NUCLEOSIDE ANALOGS | PNP, SAMHD1, HAVCR2 | NT5E 83/4885HINT1 136/4885LMNA 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.